Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) PT at $18.42

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $18.42.

ALXO has been the topic of a number of recent analyst reports. Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and upped their target price for the company from $8.00 to $18.00 in a research report on Friday, December 8th. Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th.

Insider Transactions at ALX Oncology

In other ALX Oncology news, CEO Jason Lettmann acquired 4,400 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was purchased at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Jason Lettmann bought 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was purchased at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Shelly Pinto sold 2,717 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $13.60, for a total value of $36,951.20. Following the sale, the chief accounting officer now owns 78,591 shares in the company, valued at approximately $1,068,837.60. The disclosure for this sale can be found here. Corporate insiders own 50.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ALXO. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of ALX Oncology in the 4th quarter valued at approximately $28,000. Royal Bank of Canada increased its holdings in ALX Oncology by 226.6% in the second quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock valued at $30,000 after buying an additional 2,776 shares during the last quarter. Legal & General Group Plc raised its stake in ALX Oncology by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after buying an additional 684 shares in the last quarter. UBS Group AG lifted its holdings in ALX Oncology by 38.7% during the 1st quarter. UBS Group AG now owns 10,043 shares of the company’s stock worth $45,000 after buying an additional 2,801 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of ALX Oncology during the 3rd quarter worth about $48,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Stock Down 2.3 %

Shares of NASDAQ ALXO opened at $11.15 on Friday. ALX Oncology has a 1 year low of $3.94 and a 1 year high of $17.42. The company has a market capitalization of $559.17 million, a P/E ratio of -2.97 and a beta of 1.63. The company has a 50 day simple moving average of $14.07 and a 200-day simple moving average of $11.15. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). On average, equities research analysts predict that ALX Oncology will post -3.33 earnings per share for the current year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.